Management of chronic lymphocytic leukemia (CLL), in first-line and relapsed/refractory settings, has been revolutionized by the introduction of oral, targeted agents against Bruton Tyrosine Kinase (ibrutinib), PI-3Kinase (idelalisib), and Bcl-2 (venetoclax) [1,2]. This evidence concerns the gene BCL2 and B-cell chronic lymphocytic leukemia.